These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 32322109)

  • 1. Use of Taxanes in Metastatic HER2-negative Breast Cancer - a Status Report.
    Gluz O; Kolberg-Liedtke C; Marmé F; Thill M
    Geburtshilfe Frauenheilkd; 2020 Apr; 80(4):399-409. PubMed ID: 32322109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment of the Certification System "Gynaecological Dysplasia" in Germany.
    Beckmann MW; Quaas J; Bischofberger A; Kämmerle A; Lux MP; Wesselmann S
    Geburtshilfe Frauenheilkd; 2014 Sep; 74(9):860-867. PubMed ID: 25278628
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
    Takashima T; Mukai H; Hara F; Matsubara N; Saito T; Takano T; Park Y; Toyama T; Hozumi Y; Tsurutani J; Imoto S; Watanabe T; Sagara Y; Nishimura R; Shimozuma K; Ohashi Y;
    Lancet Oncol; 2016 Jan; 17(1):90-8. PubMed ID: 26617202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Taxane-containing regimens for metastatic breast cancer.
    Ghersi D; Willson ML; Chan MM; Simes J; Donoghue E; Wilcken N
    Cochrane Database Syst Rev; 2015 Jun; 2015(6):CD003366. PubMed ID: 26058962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
    Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.
    Palumbo R; Sottotetti F; Trifirò G; Piazza E; Ferzi A; Gambaro A; Spinapolice EG; Pozzi E; Tagliaferri B; Teragni C; Bernardo A
    Drug Des Devel Ther; 2015; 9():2189-99. PubMed ID: 25931813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic effect of taxanes on metastatic breast cancer of various immunohistochemical subtypes.
    Fukada I; Araki K; Kobayashi K; Kobayashi T; Horii R; Akiyama F; Takahashi S; Iwase T; Ito Y
    Oncol Lett; 2016 Jul; 12(1):663-669. PubMed ID: 27347197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational study.
    Vasseur A; Carton M; Guiu S; Augereau P; Uwer L; Mouret-Reynier MA; Levy C; Eymard JC; Ferrero JM; Leheurteur M; Goncalves A; Robert M; De La Motte Rouge T; Bachelot T; Petit T; Debled M; Grinda T; Desmoulins I; Vanlemmens L; Nicolaï V; Simon G; Cabel L
    Breast; 2022 Oct; 65():136-144. PubMed ID: 35944353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) - Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities.
    Emons G; Steiner E; Vordermark D; Uleer C; Bock N; Paradies K; Ortmann O; Aretz S; Mallmann P; Kurzeder C; Hagen V; van Oorschot B; Höcht S; Feyer P; Egerer G; Friedrich M; Cremer W; Prott FJ; Horn LC; Prömpeler H; Langrehr J; Leinung S; Beckmann MW; Kimmig R; Letsch A; Reinhardt M; Alt-Epping B; Kiesel L; Menke J; Gebhardt M; Steinke-Lange V; Rahner N; Lichtenegger W; Zeimet A; Hanf V; Weis J; Mueller M; Henscher U; Schmutzler RK; Meindl A; Hilpert F; Panke JE; Strnad V; Niehues C; Dauelsberg T; Niehoff P; Mayr D; Grab D; Kreißl M; Witteler R; Schorsch A; Mustea A; Petru E; Hübner J; Rose AD; Wight E; Tholen R; Bauerschmitz GJ; Fleisch M; Juhasz-Boess I; Lax S; Runnebaum I; Tempfer C; Nothacker MJ; Blödt S; Follmann M; Langer T; Raatz H; Wesselmann S; Erdogan S
    Geburtshilfe Frauenheilkd; 2018 Nov; 78(11):1089-1109. PubMed ID: 30581199
    [No Abstract]   [Full Text] [Related]  

  • 10. Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
    Ward S; Simpson E; Davis S; Hind D; Rees A; Wilkinson A
    Health Technol Assess; 2007 Oct; 11(40):1-144. PubMed ID: 17903394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
    Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
    Trials; 2020 May; 21(1):391. PubMed ID: 32381018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Taxane rechallenge during metastatic disease in HER-2 negative breast cancer patients: Clinical activity, tolerance and survival results.
    Réda M; Fouquier A; Desmoulins I; Mayeur D; Kaderbhai C; Ilie S; Hennequin A; Coudert B; Bertaut A; Ladoire S
    Breast; 2023 Apr; 68():149-156. PubMed ID: 36773403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.
    Wöckel A; Festl J; Stüber T; Brust K; Krockenberger M; Heuschmann PU; Jírů-Hillmann S; Albert US; Budach W; Follmann M; Janni W; Kopp I; Kreienberg R; Kühn T; Langer T; Nothacker M; Scharl A; Schreer I; Link H; Engel J; Fehm T; Weis J; Welt A; Steckelberg A; Feyer P; König K; Hahne A; Baumgartner T; Kreipe HH; Knoefel WT; Denkinger M; Brucker S; Lüftner D; Kubisch C; Gerlach C; Lebeau A; Siedentopf F; Petersen C; Bartsch HH; Schulz-Wendtland R; Hahn M; Hanf V; Müller-Schimpfle M; Henscher U; Roncarati R; Katalinic A; Heitmann C; Honegger C; Paradies K; Bjelic-Radisic V; Degenhardt F; Wenz F; Rick O; Hölzel D; Zaiss M; Kemper G; Budach V; Denkert C; Gerber B; Tesch H; Hirsmüller S; Sinn HP; Dunst J; Münstedt K; Bick U; Fallenberg E; Tholen R; Hung R; Baumann F; Beckmann MW; Blohmer J; Fasching P; Lux MP; Harbeck N; Hadji P; Hauner H; Heywang-Köbrunner S; Huober J; Hübner J; Jackisch C; Loibl S; Lück HJ; von Minckwitz G; Möbus V; Müller V; Nöthlings U; Schmidt M; Schmutzler R; Schneeweiss A; Schütz F; Stickeler E; Thomssen C; Untch M; Wesselmann S; Bücker A; Buck A; Stangl S
    Geburtshilfe Frauenheilkd; 2018 Nov; 78(11):1056-1088. PubMed ID: 30581198
    [No Abstract]   [Full Text] [Related]  

  • 14. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer.
    Chan A; Miles DW; Pivot X
    Ann Oncol; 2010 Dec; 21(12):2305-2315. PubMed ID: 20335367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taxanes for adjuvant treatment of early breast cancer.
    Ferguson T; Wilcken N; Vagg R; Ghersi D; Nowak AK
    Cochrane Database Syst Rev; 2007 Oct; (4):CD004421. PubMed ID: 17943815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer.
    Schneeweiss A; Bauerfeind I; Fehm T; Janni W; Thomssen C; Witzel I; Wöckel A; Müller V
    Breast Care (Basel); 2020 Dec; 15(6):608-618. PubMed ID: 33447235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
    Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS
    Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The curability of breast cancer and the treatment of advanced disease.
    Guarneri V; Conte PF
    Eur J Nucl Med Mol Imaging; 2004 Jun; 31 Suppl 1():S149-61. PubMed ID: 15107948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.